Stockscreener 앱 받기
0.7665
0.57%
0.00435
시간 외 거래:
.75
-0.0165
-2.15%
Connect Biopharma Holdings Ltd 주식(CNTB)의 최신 뉴스
Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher - Zacks Investment Research
Alps Group (Nasdaq:ALPS)Stock Analysis - simplywall.st
A holder reports sole voting power over 400,000 Connect Biopharma (CNTB) shares, plus shared ownership. - Stock Titan
Q3 EPS Estimate for Connect Biopharma Reduced by Analyst - MarketBeat
Connect Biopharma Holdings (NasdaqGM:CNTB) Stock Forecast & Analyst Predictions - Simply Wall Street
Preliminary results at Connect Biopharma (CNTB) show fewer treatment failures but a missed lung-function target. - Stock Titan
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation - sg.finance.yahoo.com
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation - Yahoo Finance
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation - GlobeNewswire
A COPD treatment cut hospital stays and ER visits for new flare-ups by 100% vs placebo through Week 4 - Stock Titan
Connect Biopharma Holdings Limited (CNTB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Connect Biopharma Holdings (Nasdaq:CNTB)Stock Analysis - simplywall.st
CNTB Stock Pulls Back As Rademikibart Data Fuels New Catalysts - timothysykes.com
CNTB Stock Pulls Back As Rademikibart Data Fuels New Catalysts - www.timothysykes.com
FEV1 well done, will FDA Connect the phase II asthma dots? - BioWorld News
Form 8K Connect Biopharma Holdings Ltd For: 15 September By Investing.com - Investing.com Canada
Form 8K Connect Biopharma Holdings Ltd For: 15 September By Investing.com - Investing.com UK
Connect Biopharma (CNTB) asthma trial cuts failures 66% but misses main goal - Stock Titan
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation - GlobeNewswire
CNTB Stock Slides As Traders Weigh Cash Runway And Volatility - www.timothysykes.com
CNTB Stock Whipsaws As Traders Weigh Cash Runway And Losses - Timothy Sykes
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation - Yahoo Finance
An asthma drug reduced treatment failures 66%—but missed statistical significance - Stock Titan
Form 8K Connect Biopharma Holdings Ltd For: 15 September By Investing.com - Investing.com India
CNTB News | CONNECT BIOPHARMA HOLDINGS L (NASDAQ:CNTB) - ChartMill
A Sept. 15 live webcast will feature Connect Biopharma management - Stock Titan
We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate - simplywall.st
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Consensus Rating of "Moderate Buy" by Analysts - marketbeat.com
Connect Biopharma stock rating reiterated at Buy by Canaccord - Investing.com South Africa
Connect Biopharma stock rating reiterated at Buy by Canaccord - Investing.com Canada
Connect Biopharma stock rating reiterated at Buy by Canaccord - Investing.com
CCORF Maintains Connect Biopharma(CNTB.US) With Buy Rating, Raises Target Price to $7 - Moomoo
Will Connect Biopharma (CNTB) Breathe Easy After Seabreeze Trials? - RTTNews
Connect (CNTB) Financial Results: Reported EPS Misses Expectations in the Reported Period; Share Response: Shares Close 7.32% Lower on the DayPretax Income Report - https://www.dars.gov.et/
Connect Biopharma Holdings Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
HC Wainwright Issues Pessimistic Forecast for CNTB Earnings - MarketBeat
Connect Biopharma (NASDAQ:CNTB) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Ikarian Capital (CNTB) discloses 6.9% Connect Biopharma holding on Schedule 13G/A - Stock Titan
Connect Biopharma (CNTB) investor Wei Zheng discloses 4% beneficial stake - Stock Titan
Connect Biopharma Holdings Ltd expected to post a loss of 21 cents a shareEarnings Preview - TradingView
H.C. Wainwright Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Connect Biopharma Holdings earnings beat by ¥0.33, revenue topped estimates - Investing.com Canada
Connect Biopharma Holdings earnings beat by ¥0.34, revenue topped estimates - Investing.com
Connect Biopharma Q2 Results: Net Loss Widens To $17.3 Million - scanx.trade
Connect Biopharma (NASDAQ:CNTB) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
Connect Biopharma (CNTB) ramps rademikibart spend as losses deepen in 2026 - Stock Titan
Connect Biopharma Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Connect Biopharma (CNTB) widens Q2 2026 loss as R&D rises, cash at $31.5M - Stock Titan
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update - finance.yahoo.com
0.62%
2.90%
자본화:
|
볼륨(24시간):